View Older Stories View More Recent Stories

Jan 5, 2022 06:30AM FDA Accepts Samsung Bioepis’ and Organon’s sBLA for their Citrate-Free, High-Concentration HUMIRA® (Adalimumab) Biosimilar Candidate
Jan 4, 2022 05:00PM Merck to Present at the 40th Annual J.P. Morgan Healthcare Conference
Dec 29, 2021 05:15PM MilliporeSigma Announces $136.7 Million U.S. Government Contract Award for New Lateral Flow Membrane Production Facility in Sheboygan, Wisconsin
Dec 27, 2021 06:47AM Merck's (MRK) KEYTRUDA Plus LENVIMA Approved in Japan for Patients With Unresectable, Advanced or Recurrent Endometrial Carcinoma That Progressed After Cancer Chemotherapy
Dec 27, 2021 06:45AM KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Patients With Unresectable, Advanced or Recurrent Endometrial Carcinoma That Progressed After Cancer Chemotherapy
Dec 27, 2021 05:38AM Merck (MRK) and Ridgeback Announce Molnupiravir Receives Special Approval for Emergency in Japan
Dec 24, 2021 06:45AM Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, Receives Special Approval for Emergency in Japan
Dec 23, 2021 11:08AM Merck (MRK) , Ridgeback’s Molnupiravir Receives U.S. FDA EUA for Treatment of High-Risk Adults With Mild to Moderate COVID-19
Dec 23, 2021 11:08AM Merck and Ridgeback’s Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-Risk Adults With Mild to Moderate COVID-19
Dec 22, 2021 06:00AM Merck (MRK) and Ridgeback Announce UK Order for Additional 1.75 Million Courses of Molnupiravir
Dec 22, 2021 06:00AM Merck and Ridgeback Announce U.K. Government to Purchase Additional 1.75 Million Courses of Molnupiravir
Dec 17, 2021 07:00AM TEPMETKO® (tepotinib) Receives Positive CHMP Opinion for Patients with Advanced NSCLC with METex14 Skipping Alterations
Dec 17, 2021 06:45AM Merck (MRK) Receives Positive EU CHMP Opinion for KEYTRUDA as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma Following Surgery
Dec 17, 2021 06:45AM Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma Following Surgery
Dec 16, 2021 05:22PM Merck (MRK) And Ridgeback Announce Publication of Phase 3 Study of Molnupiravir
Dec 16, 2021 05:19PM Merck and Ridgeback Announce Publication of Phase 3 Study of Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, in the New England Journal of Medicine
Dec 15, 2021 06:45AM Merck's (MRK) VAXNEUVANCE Approved in the EU for Individuals 18 Years of Age and Older
Dec 15, 2021 06:45AM European Commission Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Individuals 18 Years of Age and Older
Dec 15, 2021 06:45AM ADDING and REPLACING European Commission Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Individuals 18 Years of Age and Older
Dec 13, 2021 05:03PM Merck (MRK) Announces FDA Holds on Studies Evaluating Islatravir for the Treatment and Prevention of HIV-1 Infection
Dec 13, 2021 05:00PM Merck Announces Clinical Holds on Studies Evaluating Islatravir for the Treatment and Prevention of HIV-1 Infection
Dec 13, 2021 06:45AM Merck Issues $1 Billion Inaugural Sustainability Bond
Dec 7, 2021 06:15AM Merck Announces Additional $150M Investment Through 2025 to Help End Maternal Mortality Inequities
Dec 6, 2021 05:01PM Merck (MRK) Pauses Enrollment for Two Phase 3 Clinical Trials of Investigational, Once-Monthly, Oral Islatravir at the Recommendation of eDMC
Dec 6, 2021 05:00PM Merck Announces Pause in Enrollment for Two Phase 3 Clinical Trials of Investigational, Once-Monthly, Oral Islatravir for Pre-Exposure Prophylaxis (PrEP) of HIV-1 infection
Dec 6, 2021 05:18AM Merck (MRK) Reports FDA Approval of KEYTRUDA as Adjuvant Treatment for Adult and Pediatric Patients With Stage IIB or IIC Melanoma Following Complete Resection
Dec 3, 2021 06:15PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Pediatric (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection
Dec 1, 2021 06:46AM Merck (MRK) Announces U.S. FDA Accepts for Priority Review the SBLA for VAXNEUVANCE for Use in Infants and Children
Dec 1, 2021 06:45AM U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children
Nov 30, 2021 05:54PM Merck (MRK), Ridgeback Confirm FDA Advisory Committee Voted 13-10 in Favor of COVID-19 Antiviral Drug Molnupiravir
Nov 30, 2021 05:51PM Merck and Ridgeback Statement on Positive FDA Advisory Committee Vote for Investigational Oral Antiviral Molnupiravir for Treatment of Mild to Moderate COVID-19 in High Risk Adults
Nov 30, 2021 02:48PM Merck Announces First-Quarter 2022 Dividend
Nov 30, 2021 06:45AM Merck (MRK) Announces KEYTRUDA Approved in Japan in Combination With Chemotherapy for First-Line Treatment of Patients With Radically Unresectable, Advanced or Recurrent Esophageal Carcinoma
Nov 30, 2021 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Approved in Japan in Combination With Chemotherapy for First-Line Treatment of Patients With Radically Unresectable, Advanced or Recurrent Esophageal Carcinoma
Nov 30, 2021 06:30AM FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) as Adjuvant Treatment in BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer and Grants Priority
Nov 29, 2021 09:30AM Pre-Open Stock Movers 11/29: (KRYS) (ADGI) (TWTR) Higher; (MRK) (UPS) Lower (more...)
Nov 29, 2021 06:50AM Merck (MRK) Announces European Commission Approves KEYTRUDA Plus LENVIMA for Patients With Certain Types of Endometrial Carcinoma
Nov 29, 2021 06:50AM European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) for Patients With Certain Types of Endometrial Carcinoma
Nov 29, 2021 06:46AM Merck (MRK) Announces European Commission Approves KEYTRUDA Plus LENVIMA as First-Line Treatment for Adult Patients With Advanced RCC
Nov 29, 2021 06:45AM European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma
Nov 29, 2021 05:52AM Merck (MRK) and Eisai Announces EU Approval of LENVIMA Plus KEYTRUDA as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma
Nov 26, 2021 06:46AM Merck (MRK), Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19
Nov 26, 2021 06:45AM Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19
Nov 24, 2021 06:45AM Merck to Present at the 4th Annual Evercore ISI HealthCONx Conference
Nov 22, 2021 06:45AM Merck (MRK) Completes Acquisition of Acceleron Pharma (XLRN)
Nov 22, 2021 06:45AM Merck Completes Acquisition of Acceleron Pharma Inc.
Nov 22, 2021 06:26AM Merck (MRK) Completes Tender Offer to Acquire Acceleron Pharma (XLRN)
Nov 19, 2021 06:06PM Merck Completes Tender Offer to Acquire Acceleron Pharma Inc.
Nov 18, 2021 07:21PM Merck (MRK) Stops Dosing in Phase 2 Trial of MK-8507 and Islatravir for the Treatment of HIV-1
Nov 18, 2021 05:57PM Merck Provides Update on Phase 2 Clinical Trial of Once-Weekly Investigational Combination of MK-8507 and Islatravir for the Treatment of People Living with HIV-1
View More Recent Stories View Older Stories